<p>The company earned $3.21 billion, or $1.15 per share — down from $3.33 billion, or $1.17 a share, a year ago.<br /><br />Revenue totaled $15.24 billion, down more than seven per cent, partly on a combined drop in sales of nearly $1 billion for two drugs with recent generic competition. <br /><br />Despite lower sales and profit this quarter, J&J confirmed its profit forecast for the full year, at $4.45 to $4.55 per share. Sales were down across the board — in US and abroad, and in all segments.</p>
<p>The company earned $3.21 billion, or $1.15 per share — down from $3.33 billion, or $1.17 a share, a year ago.<br /><br />Revenue totaled $15.24 billion, down more than seven per cent, partly on a combined drop in sales of nearly $1 billion for two drugs with recent generic competition. <br /><br />Despite lower sales and profit this quarter, J&J confirmed its profit forecast for the full year, at $4.45 to $4.55 per share. Sales were down across the board — in US and abroad, and in all segments.</p>